Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial
诺和诺德CagriSema在减重正面对比试验中不敌礼来泽普宝

Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday.
丹麦公司诺和诺德周一表示，其GLP-1/胰淀素联合药物CagriSema在一项正面对比研究中不如礼来已上市的肥胖治疗注射剂泽普宝(Zepbound)。